YD02-2022

N/A

Report date: 2023/08/16 20:01:10

Base Information

Drug NameYD02-2022
Drug Alias NameAllogeneic Transplantation of Expanded Pancreatic Islet Cells therapy(Shanghai Jiaotong University School Of Medicine)YD02-2022
ClassificationCell and gene therapy > Cell therapy > Somatic cell > Pancreatic islet cell therapyCell and gene therapy > Cell therapy > Source of cells > Pancreatic islet-derivedCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsDiabetes Mellitus, Type 1
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Jiao Tong University School of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jiao Tong University School of Medicine
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A